356 related articles for article (PubMed ID: 18815269)
1. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
Boileau I; Rusjan P; Houle S; Wilkins D; Tong J; Selby P; Guttman M; Saint-Cyr JA; Wilson AA; Kish SJ
J Neurosci; 2008 Sep; 28(39):9850-6. PubMed ID: 18815269
[TBL] [Abstract][Full Text] [Related]
2. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.
Boileau I; Houle S; Rusjan PM; Furukawa Y; Wilkins D; Tong J; Selby P; Wilson AA; Kish SJ
Synapse; 2010 Jun; 64(6):417-20. PubMed ID: 20169578
[TBL] [Abstract][Full Text] [Related]
3. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
[TBL] [Abstract][Full Text] [Related]
4. Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.
Narendran R; Jedema HP; Lopresti BJ; Mason NS; Himes ML; Bradberry CW
Biol Psychiatry; 2015 Mar; 77(5):488-92. PubMed ID: 25062684
[TBL] [Abstract][Full Text] [Related]
5. Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.
Boileau I; McCluskey T; Tong J; Furukawa Y; Houle S; Kish SJ
Neuropsychopharmacology; 2016 Mar; 41(4):1179-87. PubMed ID: 26321315
[TBL] [Abstract][Full Text] [Related]
6. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration.
Tong J; Wilson AA; Boileau I; Houle S; Kish SJ
Synapse; 2008 Nov; 62(11):873-6. PubMed ID: 18720517
[TBL] [Abstract][Full Text] [Related]
7. In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.
Narendran R; Lopresti BJ; Martinez D; Mason NS; Himes M; May MA; Daley DC; Price JC; Mathis CA; Frankle WG
Am J Psychiatry; 2012 Jan; 169(1):55-63. PubMed ID: 22193525
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
Bohnen NI; Albin RL; Koeppe RA; Wernette KA; Kilbourn MR; Minoshima S; Frey KA
J Cereb Blood Flow Metab; 2006 Sep; 26(9):1198-212. PubMed ID: 16421508
[TBL] [Abstract][Full Text] [Related]
9. Deuterated
Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
[TBL] [Abstract][Full Text] [Related]
10. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 10-(11) C-dihydrotetrabenazine as a vesicular monoamine transporter 2 radioligand.
Li X; Chen Z; Tang J; Liu C; Zou P; Huang H; Tan C; Yu H
Arch Pharm (Weinheim); 2014 May; 347(5):313-9. PubMed ID: 24497196
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
[TBL] [Abstract][Full Text] [Related]
13. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
De La Fuente-Fernández R; Furtado S; Guttman M; Furukawa Y; Lee CS; Calne DB; Ruth TJ; Stoessl AJ
Synapse; 2003 Jul; 49(1):20-8. PubMed ID: 12710012
[TBL] [Abstract][Full Text] [Related]
14. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
[TBL] [Abstract][Full Text] [Related]
15. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Frey KA; Koeppe RA; Kilbourn MR; Vander Borght TM; Albin RL; Gilman S; Kuhl DE
Ann Neurol; 1996 Dec; 40(6):873-84. PubMed ID: 9007092
[TBL] [Abstract][Full Text] [Related]
16. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations.
Hogan KA; Staal RG; Sonsalla PK
J Neurochem; 2000 May; 74(5):2217-20. PubMed ID: 10800969
[TBL] [Abstract][Full Text] [Related]
17. A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2.
Huang ZR; Tsai CL; Huang YY; Shiue CY; Tzen KY; Yen RF; Hsin LW
PLoS One; 2016; 11(9):e0161295. PubMed ID: 27612194
[TBL] [Abstract][Full Text] [Related]
18. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
Ma JH; Dong C; Qiao HW; Barret O; Tamagnan GD; Mao W; Xu EH; Zhang C; Lu J; Chan P; Liu SY
Mov Disord; 2024 May; 39(5):847-854. PubMed ID: 38477228
[TBL] [Abstract][Full Text] [Related]
19. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users.
Little KY; Krolewski DM; Zhang L; Cassin BJ
Am J Psychiatry; 2003 Jan; 160(1):47-55. PubMed ID: 12505801
[TBL] [Abstract][Full Text] [Related]
20. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome.
Meyer P; Bohnen NI; Minoshima S; Koeppe RA; Wernette K; Kilbourn MR; Kuhl DE; Frey KA; Albin RL
Neurology; 1999 Jul; 53(2):371-4. PubMed ID: 10430428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
